You are here

Treprostinil Data for Pulmonary Hypertension Presented at Heart, Lung Meeting

SILVER SPRING, Md., April 14 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that a team of eight doctors presented a paper entitled "Two-Year Experience with Continuous Subcutaneous Treprostinil (Prostacyclin Stable Analogue) in Severe Pulmonary Hypertension Treatment" at the International Society of Heart and Lung Transplantation Annual Meeting in Vienna, Austria on April 11, 2003. The paper concluded, "In patients with severe pulmonary hypertension, long-term therapy with treprostinil (Remodulin) (1) improves NYHA function class and exercise tolerance and (2) improves long term survival and (3) there were no severe side effects related to the delivery system." The abstract for the paper is published in the January 2003 issue of the Journal of Heart and Lung Transplantation.

"We are very pleased to see ever-longer periods of satisfactory experience with Remodulin," said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. "We gain much inspiration from the knowledge that Remodulin is proving so helpful to clinicians in treating their patients with pulmonary arterial hypertension."

Remodulin received United States Food and Drug Administration approval on May 21, 2002 for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs